CBT Plus SMC Compared to SMC for Persistent Physical Symptoms in Secondary Care (PRINCE)

Persistent Physical Symptoms (PPS) Clinical Trial

— PRINCE  

Official title:

The PRINCE Secondary Study: Persistent Physical Symptoms Reduction Intervention: a System Change and Evaluation in Secondary Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02426788
• Other study ID #: STR130202 (Secondary)
• Status: Completed
• Phase: N/A
• Start date: July 2015
• Est. completion date: January 2019

Study information

• Verified date: August 2018
• Source: King's College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Brief Summary: Persistent Physical Symptoms (PPS), also known as medically unexplained symptoms (MUS) is a term used to describe a range of persistent bodily symptoms for which the exact cause is unclear. Between 20 and 40% of patients in primary care, and about 50% in secondary care experience PPS. Not only are PPS common, but the overlap across different patient groups may indicate that these phenomena are transdiagnostic. PPS are associated with profound disability and high health care costs, and if left untreated the prognosis of these patients is poor. There is an accumulating body of evidence demonstrating that cognitive behavioural interventions can reduce levels of symptoms and improve functioning in patients with PPS. A pragmatic randomised controlled trial (RCT) was designed to evaluate the clinical and cost-effectiveness of cognitive behavioural therapy (CBT) + Standard Medical Care (SMC) versus Standard Medical Care alone, in the treatment of patients with PPS. The trial will focus on patients with a variety of symptoms (e.g., non-cardiac chest pain, fibromyalgia), across secondary care clinics (e.g., neurology, cardiology, and rheumatology).

Description:

Background and study aims In primary care between 20 and 40% of patients have medically unexplained physical symptoms. The term medically unexplained symptoms (MUS) is commonly used by health care professionals. However a survey of a healthy population and a separate survey of patients with chronic fatigue syndrome (CFS) suggested that the term persistent physical symptoms (PPS) was the preferred term. The term PPS may have its drawbacks, but it will be used in the rest of this document to cover MUS as well as any other terms that may be used in the literature and clinical settings to refer to these symptoms. In secondary care, about 50% of patients have PPS, in many specialties. PPS are associated with profound disability and high health care costs. Around 50% of sufferers have co-morbid anxiety and depression and sleep problems. Left untreated, the prognosis of these patients is poor.

This study is a pragmatic RCT that will evaluate the clinical and cost-effectiveness of cognitive behavioural therapy + standard medical care (CBT+SMC), which involves 8 sessions of CBT, versus standard medical care (SMC) in the treatment of patients with PPS.

Who can participate? Patients with various PPS, such as fibromyalgia, non-cardiac chest pain, irritable bowel syndrome and a range of neurological symptoms e.g., weakness will be recruited. Participants will be recruited from clinics in secondary care (e.g., neurology, cardiology, rheumatology) at various hospitals in London.

What does the study involve? Potential participants will be identified by clinical staff who will refer them to the research team. Patients who give their consent to take part in the study will complete a number of questionnaires asking about their symptoms and use of health care services, and about their thoughts, feelings, and beliefs related to their PPS (i.e., baseline). This will take approximately 1.5 hours. After this research assessment, half of participants will be randomly assigned to the treatment arm (CBT+SMC), or to the control (SMC) arm. Participants in the treatment arm will receive 8 individual sessions of CBT (weekly or fortnightly sessions). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve their quality of life. Participants in the SMC group will receive usual medical care within the clinic.

Participants in both arms will also be asked to complete questionnaires at 9, 20, 40, and 52 weeks after randomisation. The assessment will be independent of the health care professionals delivering care.

What are the possible benefits and risks of participating? By taking part in the study patients may get helpful information about their condition. If assigned to the CBT+SMC arm, patients will receive 8 sessions of CBT focused on helping them manage their symptoms, which may improve their symptoms and increase their psychosocial functioning. It is unclear whether CBT for patients with PPS is effective; this trial will assess whether there are benefits to receiving it. Patients may benefit from being followed up closely and completing measures. It is not expected that participation in the study is associated with risks. The therapists involved in the trial are highly qualified specialists with extensive experience in treating patients with PPS. The trial team also includes a psychiatrist who will further ensure patient safety in complex cases. Participants will be free to take a break at any point during the meetings and are free to withdraw from the study at any point. Participants will also be informed that they can raise any concerns they may have with the research team and will be provided with the Patient Advice & Liaison Service contact information.

Where is the study run from? The study has been set up by the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College London and the South London and Maudsley National Health Service (NHS) Foundation Trust, and will be conducted at several hospitals in London/Greater London, including Guy's and St Thomas' Hospitals, King's College Hospital, Princess Royal University Hospital, Royal Free Hospital, University Hospital Lewisham and Queen Elizabeth Hospital.

When is the study starting and how long is it expected to run for? The study has started in July 2015 and the end date for the project is March 2019.

Who is funding the study? The study is funded by the Guy's and St. Thomas' Charity.

Who is the main contact? Prof Trudie Chalder trudie.chalder@kcl.ac.uk

Recruitment information / eligibility

• Status: Completed
• Enrollment: 324
• Est. completion date: January 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

• Adults (18 - 70 yrs)

• Patients with PPS from broad patient populations (e.g., fibromyalgia, non-cardiac chest pain, postural orthostatic tachycardia syndrome, neurological symptoms);

• Significant functional impairment/moderately severe disability - as indicated by the Work and Social Adjustment Scale (WSAS) score (i.e., a minimum score of 10);

• Ability to complete diaries and questionnaires in English;

• Willingness to complete all trial visits;

• Ability to give written informed consent.

Exclusion Criteria:

• Active psychosis;

• Factitious disorder;

• Headaches as the only PPS;

• Non-epileptic seizures

• Current alcohol dependence or drug addiction as assessed by the clinician;

• Current benzodiazepine use exceeding the equivalent of 10mg diazepam/day;

• The patient is currently receiving CBT/CBT based approach psychotherapy, or has received CBT/CBT based approach psychotherapy in the past year, for their PPS;

• The patient is thought to be at imminent risk of self-harm;

• Patient is taking part in PRINCE Primary trial.

Related Conditions & MeSH terms

• Persistent Physical Symptoms (PPS)

Intervention

Behavioral:
• Cognitive behavioural therapy (CBT)
Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.

Locations

Country	Name	City	State
United Kingdom	Guy's Hospital	London
United Kingdom	King's College Hospital	London
United Kingdom	Queen Elizabeth Hospital	London
United Kingdom	Royal Free Hospital	London
United Kingdom	St Thomas' Hospital	London
United Kingdom	University Hospital Lewisham	London
United Kingdom	Princess Royal University Hospital	Orpington

Sponsors (2)

Lead Sponsor	Collaborator
King's College London	South London and Maudsley NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	PSYCHLOPS	Measures improvement of patient-defined self-rated problems	52 weeks post randomisation
Primary	Work and social adjustment scale	Measures impairment in functioning	52 weeks post randomisation
Secondary	Persistent Physical Symptom Questionnaire	Measures severity, distress, interference and problematic nature of PPS	52 weeks post randomisation
Secondary	Patient Health Questionnaire-15 (PHQ-15)	Measures physical symptoms severity	52 weeks post randomisation
Secondary	Patient Health Questionnaire-9 (PHQ-9)	Measures mood	52 weeks post randomisation
Secondary	Generalized Anxiety Disorder-7 (GAD-7)	Measures generalised anxiety	52 weeks post randomisation
Secondary	Clinical Global Impression (CGI)	Measures patient's perception of their general health improvement	52 weeks post randomisation
Secondary	Client Service Receipt Inventory (CSRI)	Measures health care service receipt, direct and indirect costs of illness, and cost-effectiveness of interventions	52 weeks post randomisation
Secondary	EuroQol-5D (EQ-5D)	Measures health outcome	52 weeks post randomisation
Secondary	Cognitive Behavioural Responses Questionnaire	Measures beliefs and behaviours	52 weeks post randomisation
Secondary	Acceptance scale	assesses degree of acceptance of difficult symptoms	52 weeks post randomisation